Population Pharmacokinetics and Monte Carlo Simulation of Cefepime in Critically Ill Patients with Hospital-Acquired/Ventilator-Associated Pneumonia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: This study aimed to investigate the population pharmacokinetics (PK) profile and determine the optimal dosage regimen of cefepime in critically ill adult patients with hospital-acquired pneumonia (HAP) or ventilatorassociated pneumonia (VAP). Materials and Methods: Population-PK models for cefepime were developed using a nonlinear mixed-effect modeling approach. The percentage of time within 24 h in which the free concentration exceeded the minimum inhibitory concentration (MIC) at a steady state (50%fT>MIC, 100%fT>MIC, and 100%fT>4×MIC) for various combinations of dosage regimens and renal function was explored using Monte Carlo simulation. Results: Twenty-one patients were prospectively enrolled in this study. Cefepime PK was best described using a twocompartment model in which creatinine clearance (CLCR) through Cockcroft-Gault (CG) was a significant covariate for the total clearance of cefepime. The simulation results to determine the optimal cefepime dosing regimen for 50%fT>MIC as treatment target with Cmin <20 mg/L as safety target showed that a dosage regimen of 2 g through intravenous (IV) infusion every 12 h administered over 4 h was optimal at an MIC of 4 mg/L, rather than the currently recommended dosage regimen of 2 g administered through IV infusion every 8 h, in patients with normal renal function (CLCR = 90 - 130 mL/min). For a treatment target of 100%fT>MIC with Cmin <35 mg/L as a safety target, a dosage regimen of 0.75 g administered through continuous infusion over 24 h would be sufficient at an MIC equal to or less than 8 mg/L in patients with renal dysfunction (CLCR = 10 - 30 mL/min). Conclusion: Our results suggest that clinicians should consider renal function and potential neurotoxicity when deciding the dosing regimen of cefepime in critically ill patients with HAP or VAP. Therapeutic drug monitoring (TDM) to adjust cefepime trough levels may be useful to improve clinical outcomes and reduce cefepime neurotoxicity.
Abstract
Background: This study aimed to investigate the population pharmacokinetics (PK) profile and determine the optimal dosage regimen of cefepime in critically ill adult patients with hospital-acquired pneumonia (HAP) or ventilatorassociated pneumonia (VAP). Materials and Methods: Population-PK models for cefepime were developed using a nonlinear mixed-effect modeling approach. The percentage of time within 24 h in which the free concentration exceeded the minimum inhibitory concentration (MIC) at a steady state (50%fT>MIC, 100%fT>MIC, and 100%fT>4×MIC) for various combinations of dosage regimens and renal function was explored using Monte Carlo simulation. Results: Twenty-one patients were prospectively enrolled in this study. Cefepime PK was best described using a twocompartment model in which creatinine clearance (CLCR) through Cockcroft-Gault (CG) was a significant covariate for the total clearance of cefepime. The simulation results to determine the optimal cefepime dosing regimen for 50%fT>MIC as treatment target with Cmin <20 mg/L as safety target showed that a dosage regimen of 2 g through intravenous (IV) infusion every 12 h administered over 4 h was optimal at an MIC of 4 mg/L, rather than the currently recommended dosage regimen of 2 g administered through IV infusion every 8 h, in patients with normal renal function (CLCR = 90 - 130 mL/min). For a treatment target of 100%fT>MIC with Cmin <35 mg/L as a safety target, a dosage regimen of 0.75 g administered through continuous infusion over 24 h would be sufficient at an MIC equal to or less than 8 mg/L in patients with renal dysfunction (CLCR = 10 - 30 mL/min). Conclusion: Our results suggest that clinicians should consider renal function and potential neurotoxicity when deciding the dosing regimen of cefepime in critically ill patients with HAP or VAP. Therapeutic drug monitoring (TDM) to adjust cefepime trough levels may be useful to improve clinical outcomes and reduce cefepime neurotoxicity.
참고문헌 (34)
- Lepak AJ, "Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease" (2020), Elsevier
- D’Angelo RG, "Treatment options for extended-spectrum beta-lactamase(ESBL)and AmpCproducing bacteria", Expert Opin Pharmacother, 17, pp.953~967 (2016)
- Sulaiman H, "Pharmacokinetic", pharmacodynamics-optimized antimicrobial therapy in patients with hospital-acquired pneumonia, Semin Respir Crit Care Med, pp.2017, 38[DOI]
- Kalil AC, "Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia : 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society", Clin Infect Dis, 63, pp.e61~111 (2016)
- Lamoth F, "High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function", Antimicrob Agents Chemother, 54, pp.4360~4367 (2010)
- Huwyler T, "Cefepime plasma concentrations and clinical toxicity : a retrospective cohort study", Clin Microbiol Infect, 23, pp.454~459 (2017)
- Gómez CM, "Altered pharmacokinetics of ceftazidime in critically ill patients", Antimicrob Agents Chemother, 43, pp.1798~1802 (1999)
- Roberts JA, "Pharmacokinetic issues for antibiotics in the critically ill patient", Crit Care Med, 37, pp.840~851 (2009)
- Roberts JA, "Therapeutic drug monitoring of beta-lactams in critically ill patients : proof of concept", Int J Antimicrob Agents, 36, pp.332~339 (2010)
- Roberts JA, "Antibiotic resistance--what’s dosing got to do with it?", Crit Care Med, 36, pp.2433~2440 (2008)
- Hooker AC, "Conditional weighted residuals(CWRES) : a model diagnostic for the FOCE method", Pharm Res, 24, pp.2187~2197 (2007)
- Du Bois D, "A formula to estimate the approximate surface area if height and weight be known. 1916", Nutrition, 5, pp.303~311 (1989)
- Bergstrand M, "Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects models", AAPS J, 13, pp.143~151 (2011)
- Okamoto MP, "Cefepime clinical pharmacokinetics", Clin Pharmacokinet, 25, pp.88~102 (1993)
- Boschung-Pasquier L, "Cefepime neurotoxicity : thresholds and risk factors. A retrospective cohort study", Clin Microbiol Infect, 26, pp.333~339 (2020)
- Álvarez JC, "Pharmacokinetics and pharmacodynamics of cefepime in adults with hematological malignancies and febrile neutropenia after chemotherapy", Antibiotics(Basel), 10, pp.504~ (2021)
- Andes D, "In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae : application to breakpoint determinations", Antimicrob Agents Chemother, 42, pp.2375~2379 (1998)
- Woodnutt G, "Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae", Antimicrob Agents Chemother, 43, pp.29~34 (1999)
- Heffelfinger JD, "Management of community-acquired pneumonia in the era of pneumococcal resistance : a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group", Arch Intern Med, 160, pp.1399~1408 (2000)
- Craig WA, "Does the dose matter?", Clin Infect Dis, 33(Suppl 3), pp.S233~S237 (2001)
- Li C, "Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections", Antimicrob Agents Chemother, 51, pp.1725~1730 (2007)
- McKinnon PS, "Evaluation of area under the inhibitory curve(AUIC)and time above the minimum inhibitory concentration(T>MIC)as predictors of outcome for cefepime and ceftazidime in serious bacterial infections", Int J Antimicrob Agents, 31, pp.345~351 (2008)
- Roberts JA, "DALI : defining antibiotic levels in intensive care unit patients : are current β-lactam antibiotic doses sufficient for critically ill patients?", Clin Infect Dis, 58, pp.1072~1083 (2014)
- Abdul-Aziz MH, "Applying pharmacokinetic", pharmacodynamic principles in critically ill patients : optimizing efficacy and reducing resistance development, 2015, pp.36, 136~153
- Guilhaumou R, "Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics(Société Française de Pharmacologie et Thérapeutique-SFPT)and the French Society of Anaesthesia and Intensive Care Medicine(Société Française d’Anesthésie et Réanimation-SFAR)", Crit Care, 23, pp.104~ (2019)
- Scharf C, "The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome", J Intensive Care, 8, pp.86~ (2020)
- Huang H, "Continuous versus intermittent infusion of cefepime in neurosurgical patients with postoperative intracranial infections", Int J Antimicrob Agents, 43, pp.68~72 (2014)
- Sprauten PF, "Stability and antibacterial activity of cefepime during continuous infusion", Antimicrob Agents Chemother, 47, pp.1991~1994 (2003)
- Bauer KA, "Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections", Antimicrob Agents Chemother, 57, pp.2907~2912 (2013)
- Cheng V, "Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation(an ASAP ECMO study)", Int J Antimicrob Agents, 58, pp.106466~ (2021)
- Yoon Young Kyung, "Guidelines on Implementing Antimicrobial Stewardship Programs in Korea", Infection and Chemotherapy, 53(3), pp.617~659 (2021), 대한감염학회[DOI]
- Heil EL, "Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic", Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients, 2018, pp.62, ~
- Roos JF, "Pharmacokineticpharmacodynamic rationale for cefepime dosing regimens in intensive care units", J Antimicrob Chemother, 58, pp.987~993 (2006)
- Ambrose PG, "Pharmacokineticspharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases : report from the ARREST program", Antimicrob Agents Chemother, 47, pp.1643~1646 (2003)